Dronedarone
- Generic Name
- Dronedarone
- Brand Names
- Multaq
- Drug Type
- Small Molecule
- Chemical Formula
- C31H44N2O5S
- CAS Number
- 141626-36-0
- Unique Ingredient Identifier
- JQZ1L091Y2
- Background
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thrombo...
- Indication
Dronedarone is indicated for the management of atrial fibrillation (AF) in patients in sinus rhythm with a history of paroxysmal or persistent AF to reduce the risk of hospitalization.
- Associated Conditions
- Atrial Fibrillation
- Associated Therapies
- -
Effect of Prolonged Use of Dronedarone on Recurrence in Patients With Non-paroxysmal Atrial Fibrillation After Radiofrequency Ablation
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 268
- Registration Number
- NCT05655468
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
Systematic Review and Meta-Analysis of Multaq® for Safety in Atrial Fibrillation
- Conditions
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87810
- Registration Number
- NCT05279833
- Locations
- 🇫🇷
Sanofi-Aventis, France, Chilly-Mazarin, France
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- American Heart Association
- Target Recruit Count
- 3000
- Registration Number
- NCT05130268
- Locations
- 🇺🇸
The MetroHealth System, Cleveland, Ohio, United States
🇺🇸Golden Touch Clinical Research, Miami, Florida, United States
🇺🇸The Miami Research Group, Miami, Florida, United States
Prophylaxis Against Postoperative Atrial Fibrillation in Patients Undergoing On-pump CABG
- Conditions
- Interventions
- First Posted Date
- 2019-04-05
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- doaa rashwan
- Target Recruit Count
- 48
- Registration Number
- NCT03905759
- Locations
- 🇪🇬
Faculty Of Medicine, Beni-Suef University, Banī Suwayf, Egypt
Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Uppsala University Hospital
- Target Recruit Count
- 152
- Registration Number
- NCT02294955
- Locations
- 🇸🇪
Carina Blomström Lundqvist, Uppsala, Sweden
Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 98
- Registration Number
- NCT01991119
- Locations
- 🇰🇷
Cardiac and Vascular Center, Seoul, Korea, Republic of
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2020-11-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 134
- Registration Number
- NCT01522651
- Locations
- 🇬🇧
Investigational Site, London, England, United Kingdom
Dronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Rabin Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01430806
Amiodarone Compared to Dronedarone , Post Cardioversion Maintenance of Sinus Rhythm
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Eastbourne General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01266681
- Locations
- 🇬🇧
Eastbourne General Hospital, Eastbourne, East Sussex, United Kingdom
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement
- Conditions
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT01198873
- Locations
- 🇺🇸
Investigational Site Number 840031, Ocala, Florida, United States
🇺🇸Investigational Site Number 840051, St Petersburg, Florida, United States
🇺🇸Investigational Site Number 840102, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.